|
1.
|
|
9 p, 1.5 MB |
Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS) : Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups
/
Gronchi, Alessandro (Fondazione IRCCS Istituto Nazionale dei Tumori) ;
Hindi, Nadia (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Cruz, Josefina (University Hospital Canarias) ;
Blay, Jean-Yves (Center Leon Berard (Lyon)) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Italiano, Antoine (Institute Bergonie - Bourdeaux) ;
Alvarez, Rosa (Hospital General Universitario Gregorio Marañón) ;
Gutierrez, Antonio (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Rincón, Inmaculada (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Sangalli, Claudia (Fondazione IRCCS Istituto Nazionale dei Tumori) ;
Pérez Aguiar, José Luis (Hospital Universitario Canarias) ;
Romero, Jesús (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Morosi, Carlo (Fondazione IRCCS Istituto Nazionale dei Tumori) ;
Sunyach, Marie Pierre (Center Leon Berard) ;
Sanfilippo, Roberta (Fondazione IRCCS Istituto Nazionale dei Tumori) ;
Romagosa, Cleofe (Hospital Universitari Vall d'Hebron) ;
Ranchere-Vince, Dominique (Center Leon Berard) ;
Dei Tos, Angelo (University of Padova) ;
Casali, Paolo G. (University of Milan) ;
Martin-Broto, Javier (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Universitat Autònoma de Barcelona
Myxoid liposarcoma (ML) exhibits a special sensitivity to trabectedin (T) and radiation therapy (RT). Preclinical data suggest a synergistic effect. We aimed to study safety, feasibility and activity of the administration of pre-operative concurrent T and RT in patients affected by localized resectable ML. [...]
2019 -  10.1016/j.eclinm.2019.03.007
EClinicalMedicine, Vol. 9 (march 2019) , p. 35-43
|
|
|
2.
|
|
12 p, 682.4 KB |
Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib
/
Hidalgo-Ríos, Samuel (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Carrillo García, Jaime (Hospital Universitario General de Villalba. Servicio de Oncología Médica) ;
Moura, David S. (Hospital Universitario General de Villalba. Servicio de Oncología Médica) ;
Stacchiotti, Silvia (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Redondo, Andrés (Hospital Universitario La Paz. Servicio de Oncología Médica. Instituto de Investigación en Salud (IdiPAZ)) ;
Italiano, Antoine (Institut Bergonié. Department of Oncology) ;
Gutiérrez, Antonio (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Grignani, Giovanni (Candiolo Cancer Institute. FPO - IRCCS) ;
Hindi, Nadia (Hospital Universitario Fundación Jiménez Díaz. Servicio de Oncología Médica) ;
López-Guerrero, J.A (Laboratory of Molecular Biology. Fundación Instituto Valenciano de Oncología) ;
Garcia del Muro, Xavier (Institut d'Investigació Biomèdica de Bellvitge) ;
Martínez-Trufero, Javier (Hospital Universitario Miguel Servet. Servicio de Oncología Médica) ;
Palmerini, Emanuela (IRCCS Istituto Ortopedico Rizzoli (Bologna)) ;
Sebio, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Bernabeu, Daniel (Hospital Universitario La Paz. Sección de Radiología musculoesquelética) ;
Le Cesne, Axel (Gustave Roussy Cancer Campus. Department of Medical Oncology) ;
Casali, Paolo Giovanni (Fondazione IRCCS Istituto Nazionale dei Tumori. Adult Mesenchymal and Rare Tumor Unit. Department of Cancer Medicine) ;
Blay, Jean-Yves (Department of Medical Oncology. Centre Léon Bérard. Université Claude Bernard Lyon) ;
Cruz-Jurado, Josefina (Hospital Universitario de Canarias. Servicio de Oncología Médica) ;
Martín-Broto, Javier (Hospital Universitario Fundación Jiménez Díaz. Servicio de Oncología Médica)
Pazopanib was assessed prospectively in the GEIS-32 phase II study (NCT02066285) on advanced solitary fibrous tumour (SFT), resulting in a longer progression-free survival (PFS) and overall survival (OS) compared with historical controls treated with chemotherapy. [...]
2022 - 10.3390/cancers14174186
Cancers, Vol. 14 Núm. 17 (september 2022) , p. 4186
|
|
|
3.
|
|
14 p, 2.6 MB |
Epithelioid hemangioendothelioma, an ultra-rare cancer : a consensus paper from the community of experts
/
Stacchiotti, Silvia (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Miah, Aisha B. (The Royal Marsden Hospital) ;
Frezza, Anna Maria (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Messiou, Christina (Department of Radiology. The Royal Marsden Hospital and The Institute of Cancer Research) ;
Morosi, Carlo (Radiology Department. Fondazione IRCCS Istituto Nazionale Tumori) ;
Caraceni, Augusto (Fondazione IRCCS Istituto Nazionale Tumori) ;
Antonescu, Cristina (Memorial Sloan Kettering Cancer Center) ;
Bajpai, Jyoti (Homi Bhabha National Institute. Medical Oncology Department) ;
Baldini, Elizabeth Healey (Dana-Farber Cancer Center/Brigham) ;
Bauer, Sebastian (University of Duisburg-Essen) ;
Biagini, Roberto (Regina Elena National Cancer Institute) ;
Bielack, Stefan S. (Klinikum Stuttgart - Olgahospital) ;
Blay, Jean-Yves (Department of Medical Oncology. Centre Leon Berard. Université Claude Bernard Lyon. Unicancer) ;
Bonvalot, Sylvie (Institut Curie. Department of Surgical Oncology) ;
Boukovinas, Ioannis P. (Nordix) ;
Bovee, Judith V.M.G. (Leiden University Medical Center) ;
Boye, Kjetil (The Norwegian Radium Hospital) ;
Brodowicz, Thomas (Medical University Vienna) ;
Callegaro, Dario (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
De Álava, Enrique (Department of Normal and Pathological Cytology and Histology. School of Medicine. University of Seville) ;
Deoras-Sutliff, M. (The EHE Foundation) ;
Dufresne, Armelle (Department of Medical Oncology. Centre Leon Berard. Université Claude Bernard Lyon. Unicancer) ;
Eriksson, Mikael (Department of Oncology. Skane University Hospital and Lund University) ;
Errani, Costantino (Orthopaedic Service. Musculoskeletal Oncology Department. IRCCS Istituto Ortopedico Rizzoli) ;
Fedenko, Alexander (Medical Oncology Division. P.A. Herzen Cancer Research Institute) ;
Ferraresi, Virginia (Sarcomas and Rare Tumors Unit. IRCCS Regina Elena National Cancer Institute) ;
Ferrari, Andrea (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Fletcher, Christopher D.M. (Department of Pathology Brigham & Women's Hospital) ;
Garcia del Muro, Xavier (Universitat de Barcelona) ;
Gelderblom, Hans J. (Department of Medical Oncology. Leiden University Medical Center) ;
Gladdy, Rebecca A. (University of Toronto and Lunenfeld-Tanenbaum Research Institute) ;
Gouin, François (Department of Surgery. Centre Leon Berard) ;
Grignani, Giovanni (Candiolo Cancer Institute. FPO - IRCCS) ;
Gutkovich, J. (NUY Langone Medical Center) ;
Haas, Rick (Department of Radiotherapy. the Leiden University Medical Center) ;
Hindi, Nadia (Universidad de Sevilla. Instituto de Biomedicina de Sevilla) ;
Hohenberger, Peter (Mannheim University Medical Center) ;
Huang, Paul (Division of Molecular Pathology. The Institute of Cancer Research) ;
Joensuu, Heikki T. (Department of Oncology. Helsinki University Hospital & Helsinki University) ;
Jones, Robin Lewis (Department of Cancer. The Royal Marsden Hospital and The Institute of Cancer Research) ;
Jungels, Christiane (Institut Jules Bordet. Université Libre de Bruxelles) ;
Kasper, Bernd (University of Heidelberg. Mannheim University Medical Center. Sarcoma Unit) ;
Kawai, Akira (Musculoskeletal Oncology and Rehabilitation Medicine. Rare Cancer Center National Cancer Center Hospital) ;
Le Cesne, Axel (International Department. Gustave Roussy) ;
Le Grange, Franél (UCLH - University College London Hospitals NHS Foundation Trust) ;
Leithner, Andeas (Department of Orthopaedics and Trauma Medical University Graz) ;
Leonard, H. (Chair of Trustees of the EHE Rare Cancer Charity (UK). Charity number 1162472) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Martin Broto, Javier (Hospital Universitario Fundación Jiménez Díaz) ;
Merimsky, Ofer (Unit of Soft Tissue and Bone Oncology. Division of Oncology. Tel-Aviv Medical Center affiliated with Sackler School of Medicine. Tel Aviv University) ;
Merriam, Priscilla (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Department of Medical Oncology) ;
Miceli, Rosalba (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Mir, Olivier (Sarcoma Group. Gustave Roussy) ;
Molinari, Massimo (University of Pittsburgh Medical Center. Thomas Starzl Transplant Institute) ;
Montemurro, Michael (Oncology. CHUV Lausanne) ;
Oldani, Graziano (Division of Abdominal Surgery. University Hospitals of Geneva) ;
Palmerini, Emanuela (Chemotherapy Unit. IRCCS Istituto Ortopedico Rizzoli) ;
Pantaleo, Maria Abbondanza. (Division of Oncology. IRCCS Azienda Ospedaliero-Universitaria di Bologna) ;
Patel, Sapna Pradyuman (Sarcoma Center. The University of Texas M.D. Anderson Cancer Center) ;
Piperno-Neumann, Sophie (Department of Medical Oncology. Institut Curie) ;
Raut, Chandrajit Premanand (Dana Farber Cancer Center. Harvard Medical School) ;
Ravi, Vinod (Sarcoma Center. The University of Texas M.D. Anderson Cancer Center) ;
Razak, Albiruni Ryan Abdul (Princess Margaret Cancer Centre and Sinai Healthcare System & Faculty of Medicine. University of Toronto) ;
Reichardt, Peter (Helios Klinikum Berlin-Buch. Department of Oncology and Palliative Care) ;
Rubin, Brian P. (Robert J. Tomsich Pathology and Laboratory Medicine Institute. Cleveland Clinic) ;
Rutkowski, Piotr (Maria Sklodowska-Curie National Research Institute of Oncology. Department of Soft Tissue/Bone Sarcoma and Melanoma) ;
Safwat, Akmal Ahmed (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Sangalli, Claudia (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Sapisochin, Gonzalo (Multi-Organ Transplant and HPB Surgical Oncology. Division of General Surgery. Department of Surgery. University of Toronto) ;
Sbaraglia, Marta (Department of Pathology. Azienda Ospedaliera Università Padova) ;
Scheipl, Susanne (Department of Orthopaedics and Trauma. Medical University of Graz) ;
Schöffski, Patrick (Leuven Cancer Institute) ;
Strauss, Dirk Cornelius (Department of Surgery. The Royal Marsden Hospital and The Institute of Cancer Research) ;
Strauss, Sandra J. (University College London Hospital) ;
Sundby Hall, Kirsten (Department of Oncology. Oslo University Hospital. The Norwegian Radium Hospital) ;
Tap, William D. (Department of Medicine. Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College) ;
Trama, Annalisa (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Tweddle, A. (Palliative Care. The Royal Marsden Hospital and The Institute of Cancer Research London) ;
van der Graaf, Winette T.A. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
van de Sande, Michiel (Department of Orthopedic Surgery Bone and Soft Tissue Tumor Unit. Leiden University Medical Center) ;
Van Houdt, Winan (Sarcoma and Melanoma Unit. The Netherlands Cancer Institute) ;
van Oortmerssen, Gerard (Co-Chair of Sarcoma Patients EuroNet (SPAEN). Woelfersheim. Germany & Chairman of the Dutch organisation for sarcoma patients (Patiëntenplatform Sarcomen). Guest researcher at Leiden University (Leiden Institute for Advanced Computer Science). Leiden University) ;
Wagner, Andrew J. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Department of Medical Oncology) ;
Wartenberg, Markus (Chair of the Board of Directors of Sarcoma Patients EuroNet (SPAEN). Sarcoma Patients EuroNet (SPAEN)) ;
Wood, J. (The Royal Marsden NHS Foundation Trust) ;
Zaffaroni, Nadia (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Zimmermann, Camilla (Department of Supportive Care. Princess Margaret Cancer Centre and Division of Palliative Medicine. Department of Medicine. University of Toronto) ;
Casali, Paolo Giovanni (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Dei Tos, Angelo (Department of Pathology. Azienda Ospedaliera Università Padova) ;
Gronchi, Alessandro (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia))
Epithelioid hemangioendothelioma (EHE) is an ultra-rare, translocated, vascular sarcoma. EHE clinical behavior is variable, ranging from that of a low-grade malignancy to that of a high-grade sarcoma and it is marked by a high propensity for systemic involvement. [...]
2021 - 10.1016/j.esmoop.2021.100170
ESMO open, Vol. 6 Núm. 3 (june 2021) , p. 100170
|
|
|
4.
|
|
5 p, 332.1 KB |
Biosimilars : a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers
/
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Vyas, Malvika (European Society for Medical Oncology) ;
Giuliani, Rosa (San Camillo Forlanini Hospital) ;
Arnold, Dirk (CUF Hospitals) ;
Cardoso, Fatima (Champalimaud Clinical Center) ;
Casali, Paolo Giovanni (Fondazione IRCCS National Cancer Institute) ;
Cervantes, Andrés (Clinic Hospital) ;
Eggermont, Alexander (Gustave Roussy Cancer Campus Grand Paris) ;
Eniu, Alexandru (Cancer Institute "Ion Chiricuta") ;
Jassem, Jacek (Medical University of Gdansk) ;
Pentheroudakis, George (University of Ioannina) ;
Peters, Solange (Centre Hospitalier Universitaire Vaudois) ;
Rauh, Stefan (Hospital Center Emile Mayrisch) ;
Zielinski, Christoph C. (Medical University of Vienna) ;
Stahel, Rolf A. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Voest, Emile (University Hospital Zurich (Suïssa)) ;
Douillard, Jean-Yves (European Society for Medical Oncology) ;
McGregor, Keith (European Society for Medical Oncology) ;
Ciardiello, Fortunato (Second University of Naples) ;
Universitat Autònoma de Barcelona
Biosimilars present a necessary and timely opportunity for physicians, patients and healthcare systems. If suitably developed clinically, manufactured to the correct standards and used appropriately, they can positively impact on the financial sustainability of healthcare systems. [...]
2017 - 10.1136/esmoopen-2016-000142
ESMO open, Vol. 1 (january 2017)
|
|
|
5.
|
|
10 p, 1016.0 KB |
Global cancer control : responding to the growing burden, rising costs and inequalities in access
/
Prager, Gerald W. (Medical University of Vienna) ;
Braga, Sofia (Instituto CUF Oncologia) ;
Bystricky, Branislav (Faculty Hospital Trencin) ;
Qvortrup, Camilla (Odense University Hospital (Dinamarca)) ;
Criscitiello, Carmen (Istituto Europeo di Oncologia) ;
Esin, Ece (Ankara Oncology Education and Research Hospital) ;
Sonke, Gabe S. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia) ;
Frenel, Jean-Sebastian (Institut de Cancerologie de l'Ouest Saint-Herblain) ;
Karamouzis, Michalis (National and Kapodistrian University of Athens) ;
Strijbos, Michiel (AZ KLINA Hospitals) ;
Yazici, Ozan (Ankara Numune Education and Research Hospital) ;
Bossi, Paolo (Fondazione IRCCS Istituto Nazionale Tumori Milano) ;
Banerjee, Susana (Royal Marsden Hospital (Regne Unit)) ;
Troiani, Teresa (Università degli Studi della Campania Luigi Vanvitelli) ;
Eniu, Alexandru (Cancer Institute "Ion Chiricuta") ;
Ciardiello, Fortunato (Università degli Studi della Campania Luigi Vanvitelli) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Zielinski, Christoph C. (Medical University Vienna, General Hospital, and Vienna Cancer Center) ;
Casali, Paolo Giovanni (Istituto Nazionale Tumori) ;
Cardoso, Fatima (Champalimaud Clinical Center) ;
Douillard, Jean-Yves (European Society for Medical Oncology) ;
Jezdic, Svetlana (European Society for Medical Oncology) ;
McGregor, Keith (European Society for Medical Oncology) ;
Bricalli, Gracemarie (European Society for Medical Oncology) ;
Vyas, Malvika (European Society for Medical Oncology) ;
Ilbawi, André (Disability, Violence and Injury Prevention (NVI), World Health Organization)
The cancer burden is rising globally, exerting significant strain on populations and health systems at all income levels. In May 2017, world governments made a commitment to further invest in cancer control as a public health priority, passing the World Health Assembly Resolution 70. [...]
2018 - 10.1136/esmoopen-2017-000285
ESMO open, Vol. 3 (february 2018)
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
